Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Boehringer Ingelheim
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Gilead Sciences
Bristol-Myers Squibb
PrECOG, LLC.
Merck Sharp & Dohme LLC
Eli Lilly and Company
Hoffmann-La Roche
AstraZeneca
Merck Sharp & Dohme LLC
Revolution Medicines, Inc.
Verastem, Inc.
University of Chicago
Alliance for Clinical Trials in Oncology
Bristol-Myers Squibb
Pfizer
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
BioNTech SE
Taiho Oncology, Inc.
NRG Oncology
Eli Lilly and Company
Instituto Nacional de Cancerologia de Mexico
Jiangsu HengRui Medicine Co., Ltd.
Lantern Pharma Inc.
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Latin American Cooperative Oncology Group
University Hospital, Essen
Mirati Therapeutics Inc.
Ohio State University Comprehensive Cancer Center
Fox Chase Cancer Center
Sun Yat-sen University
Vanderbilt-Ingram Cancer Center
Rutgers, The State University of New Jersey
Nanfang Hospital, Southern Medical University